Endotype-driven precision medicine in chronic rhinosinusitis

References

• Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621–628.
   PubMed Web of Science ®Google Scholar
• Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015;70(5):533–539.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: european position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.
   PubMed Web of Science ®Google Scholar
• Avdeeva K, Fokkens W. Precision medicine in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep. 2018;18(4):25.
   PubMed Web of Science ®Google Scholar
• Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009;124(3):478–484.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2013;131(6):1479–1490.
   PubMed Web of Science ®Google Scholar
• Shi LL, Xiong P, Zhang L, et al. Features of airway remodeling in different types of Chinese chronic rhinosinusitis are associated with inflammation patterns. Allergy. 2013;68(1):101–109.
   PubMed Web of Science ®Google Scholar
• Pothoven KL, Norton JE, Suh LA, et al. Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease. J Allergy Clin Immunol. 2017;139(6):1966–1978.
   PubMed Web of Science ®Google Scholar
• Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122(5):961–968.
   PubMed Web of Science ®Google Scholar
• Katotomichelakis M, Tantilipikorn P, Holtappels G, et al. Inflammatory patterns in upper airway disease in the same geographical area may change over time. Am J Rhinol Allergy. 2013;27(5):354–360.
   PubMed Web of Science ®Google Scholar
• Chitsuthipakorn W, Seresirikachorn K, Sommer DD, et al. Endotypes of chronic rhinosinusitis across ancestry and geographic regions. Curr Allergy Asthma Rep. 2018;18(9):46.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Hellings PW, et al. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192(6):682–694.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Asaka D, Yoshikawa M, et al. Identification of chronic rhinosinusitis phenotypes using cluster analysis. Am J Rhinol Allergy. 2012;26(3):172–176.
   PubMed Web of Science ®Google Scholar
• Soler ZM, Hyer JM, Ramakrishnan V, et al. Identification of chronic rhinosinusitis phenotypes using cluster analysis. Int Forum Allergy Rhinol. 2015;5(5):399–407.
   PubMed Web of Science ®Google Scholar
• Lou H, Meng Y, Piao Y, et al. Cellular phenotyping of chronic rhinosinusitis with nasal polyps. Rhinology. 2016;54(2):150–159.
   PubMed Web of Science ®Google Scholar
• Cao PP, Wang ZC, Schleimer RP, et al. Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes. Ann Allergy Asthma Immunol. 2019;122(1):33–40.
   PubMed Web of Science ®Google Scholar
• Ma J, Shi LL, Deng YK, et al. CD8(+) T cells with distinct cytokine-producing features and low cytotoxic activity in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2016;46(9):1162–1175.
   PubMed Web of Science ®Google Scholar
• Derycke L, Eyerich S, Van Crombruggen K, et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PLoS One. 2014;9(6):e97581.
   PubMed Web of Science ®Google Scholar
• Soklic TK, Silar M, Rijavec M, et al. CD3+CD4−CD8− mucosal T cells are associated with uncontrolled chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;143(3):1235–1237.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019 May 22. DOI:10.1016/j.jaip.2019.05.009.
   Google Scholar
• Bachert C, Gevaert P, Holtappels G, et al. Nasal polyposis: from cytokines to growth. Am J Rhinol. 2000;14(5):279–290.
   PubMedGoogle Scholar
• Kim SJ, Lee KH, Kim SW, et al. Changes in histological features of nasal polyps in a Korean population over a 17-year period. Otolaryngol Head Neck Surg. 2013;149(3):431–437.
   PubMed Web of Science ®Google Scholar
• Shin SH, Ye MK, Kim JK, et al. Histological characteristics of chronic rhinosinusitis with nasal polyps: recent 10-year experience of a single center in Daegu, Korea. Am J Rhinol Allergy. 2014;28(2):95–98.
   PubMed Web of Science ®Google Scholar
• Wang W, Gao Y, Zhu Z, et al. Changes in the clinical and histological characteristics of Chinese chronic rhinosinusitis with nasal polyps over 11 years. Int Forum Allergy Rhinol. 2019;9(2):149–157.
   PubMed Web of Science ®Google Scholar
• Jiang WX, Cao PP, Li ZY, et al. A retrospective study of changes of histopathology of nasal polyps in adult Chinese in central China. Rhinology. 2019;57(4):261–267.
   PubMed Web of Science ®Google Scholar
• Wei B, Liu F, Zhang J, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018;56(3):216–226.
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.
   PubMed Web of Science ®Google Scholar
• Turner JH, Chandra RK, Li P, et al. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018;141(5):1895–1897.
   PubMed Web of Science ®Google Scholar
• Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73(7):1459–1469.
   PubMed Web of Science ®Google Scholar
• Yip J, Monteiro E, Chan Y. Endotypes of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2019;27(1):14–19.
   PubMed Web of Science ®Google Scholar
• Workman AD, Kohanski MA, Cohen NA. Biomarkers in chronic rhinosinusitis with nasal polyps. Immunol Allergy Clin North Am. 2018;38(4):679–692.
   PubMed Web of Science ®Google Scholar
• Yao Y, Xie S, Yang C, et al. Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis. Eur Arch Otorhinolaryngol. 2017;274(10):3559–3566.
   PubMed Web of Science ®Google Scholar
• Lou H, Meng Y, Piao Y, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015;29(5):350–356.
   PubMed Web of Science ®Google Scholar
• Meng Y, Lou H, Wang C, et al. Predictive significance of computed tomography in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2016;6(8):812–819.
   PubMed Web of Science ®Google Scholar
• DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550–555.
   PubMed Web of Science ®Google Scholar
• Van Zele T, Holtappels G, Gevaert P, et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192–198.
   PubMed Web of Science ®Google Scholar
• Wu D, Yan B, Wang Y, et al. Charcot-leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(1):345–348.
   PubMed Web of Science ®Google Scholar
• Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012;129(6):1522–1528.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447–2449.
   PubMed Web of Science ®Google Scholar
• Morse JC, Li P, Ely KA, et al. Chronic rhinosinusitis in elderly patients is associated with an exaggerated neutrophilic proinflammatory response to pathogenic bacteria. J Allergy Clin Immunol. 2019;143(3):990–1002.
   PubMed Web of Science ®Google Scholar
• Hopkins C, Slack R, Lund V, et al. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope. 2009;119(12):2459–2465.
   PubMed Web of Science ®Google Scholar
• Ishitoya J, Sakuma Y, Tsukuda M. Eosinophilic chronic rhinosinusitis in Japan. Allergol Int. 2010;59(3):239–245.
   PubMedGoogle Scholar
• Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811–813.
   PubMed Web of Science ®Google Scholar
• Tosun F, Arslan HH, Karslioglu Y, et al. Relationship between postoperative recurrence rate and eosinophil density of nasal polyps. Ann Otol Rhinol Laryngol. 2010;119(7):455–459.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Yoshikawa M, Asaka D, et al. Mucosal eosinophilia and recurrence of nasal polyps - new classification of chronic rhinosinusitis. Rhinology. 2011;49(4):392–396.
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Sakashita M, Haruna T, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study. Allergy. 2015;70(8):995–1003.
   PubMed Web of Science ®Google Scholar
• Grgic MV, Cupic H, Kalogjera L, et al. Surgical treatment for nasal polyposis: predictors of outcome. Eur Arch Otorhinolaryngol. 2016;272(12):3735–3743.
   Web of Science ®Google Scholar
• McHugh T, Snidvongs K, Xie M, et al. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018;8(12):1421–1429.
   PubMed Web of Science ®Google Scholar
• Snidvongs K, Lam M, Sacks R, et al. Structured histopathology profiling of chronic rhinosinusitis in routine practice. Int Forum Allergy Rhinol. 2012;2(5):376–385.
   PubMed Web of Science ®Google Scholar
• Ho J, Hamizan AW, Alvarado R, et al. Systemic predictors of eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2018;32(4):252–257.
   PubMed Web of Science ®Google Scholar
• Matsuwaki Y, Ookushi T, Asaka D, et al. Chronic rhinosinusitis: risk factors for the recurrence of chronic rhinosinusitis based on 5-year follow-up after endoscopic sinus surgery. Int Arch Allergy Immunol. 2008;146(Suppl 1):77–81.
   PubMed Web of Science ®Google Scholar
• Hu Y, Cao PP, Liang GT, et al. Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults. Laryngoscope. 2012;122(3):498–503.
   PubMed Web of Science ®Google Scholar
• Brescia G, Barion U, Zanotti C, et al. The prognostic role of serum eosinophil and basophil levels in sinonasal polyposis. Int Forum Allergy Rhinol. 2017;7(3):261–267.
   PubMed Web of Science ®Google Scholar
• Casale TB. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J Allergy Clin Immunol. 2017;139(5):1411–1421.
   PubMed Web of Science ®Google Scholar
• Gurrola J 2nd, Borish L. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. J Allergy Clin Immunol. 2017;140(6):1499–1508.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440.
   PubMed Web of Science ®Google Scholar
• De Greve G, Hellings PW, Fokkens WJ, et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.
   PubMed Web of Science ®Google Scholar
• Wagenmann M, Scheckenbach K, Chaker AM. Endotypes in chronic rhinosinusitis: biomarkers based on a mechanistic insight for targeted treatment? ORL J Otorhinolaryngol Relat Spec. 2017;79(1–2):78–84.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–1141.
   PubMed Web of Science ®Google Scholar
• Yan B, Lou H, Wang Y, et al. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(2):455–469.
   PubMed Web of Science ®Google Scholar
• Smith KA, Pulsipher A, Gabrielsen DA, et al. Biologics in chronic rhinosinusitis: an update and thoughts for future directions. Am J Rhinol Allergy. 2018;32(5):412–423.
   PubMed Web of Science ®Google Scholar
• Wu D, Wang J, Zhang M. Altered Th17/Treg ratio in nasal polyps with distinct cytokine profile: association with patterns of inflammation and mucosal remodeling. Medicine (Baltimore). 2016;95(10):e2998.
   PubMed Web of Science ®Google Scholar
• Wang H, Li ZY, Jiang WX, et al. The activation and function of IL-36γ in neutrophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1646–1658.
   PubMed Web of Science ®Google Scholar
• Tsou YA, Chen CM, Lin TC, et al. Decreased SPLUNC1 expression is associated with Pseudomonas infection in surgically treated chronic rhinosinusitis patients who may require repeated sinus surgery. Laryngoscope. 2013;123(4):845–851.
   PubMed Web of Science ®Google Scholar
• Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015;135(4):922–929.
   PubMed Web of Science ®Google Scholar
• Aversa S, Ondolo C, Abbadessa G, et al. Steroid resistance in nasal polyposis: role of glucocorticoid receptor and TGF-beta1. Rhinology. 2012;50(4):427–435.
   PubMed Web of Science ®Google Scholar
• Milara J, Morell A, Ballester B, et al. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;139(3):855–862.
   PubMed Web of Science ®Google Scholar
• Tuncer U, Soylu L, Aydogan B, et al. The effectiveness of steroid treatment in nasal polyposis. Auris Nasus Larynx. 2003;30(3):263–268.
   PubMed Web of Science ®Google Scholar
• Milara J, Peiro T, Armengot M, et al. Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015;135(2):470–476.
   PubMed Web of Science ®Google Scholar
• Lu H, Lin XS, Yao DM, et al. Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study. Eur Arch Otorhinolaryngol. 2018;275(2):401–408.
   PubMed Web of Science ®Google Scholar
• Hong H, Chen F, Sun Y, et al. Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2018;141(5):1890–1892.
   PubMed Web of Science ®Google Scholar
• Chen F, Hong H, Sun Y, et al. Nasal interleukin 25 as a novel biomarker for patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness: A pilot study. Ann Allergy Asthma Immunol. 2017;119(4):310–316.
   PubMed Web of Science ®Google Scholar
• Kato Y, Takabayashi T, Sakashita M, et al. Expression and functional analysis of CST1 in intractable nasal polyps. Am J Respir Cell Mol Biol. 2018;59(4):448–457.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang L. Use of biologics in chronic sinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2019;19(4):365–372.
   PubMed Web of Science ®Google Scholar
• Rivero A, Liang J. Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis. Ann Otol Rhinol Laryngol. 2017;126(11):739–747.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract. 2015;3(2):167–174.
   PubMed Web of Science ®Google Scholar
• Schneider JS. Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps. JAMA Otolaryngol Head Neck Surg. 2016;142(7):698–699.
   PubMed Web of Science ®Google Scholar
• Bachert C, AR S, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.
   PubMed Web of Science ®Google Scholar
• Radonjic-Hoesli S, Valent P, Klion AD, et al. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633–656.
   PubMed Web of Science ®Google Scholar
• Kramer MF, Ostertag P, Pfrogner E, et al. Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis. Laryngoscope. 2000;110(6):1056–1062.
   PubMed Web of Science ®Google Scholar
• De Schryver E, Derycke L, Calus L, et al. The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology. 2017;55(2):152–160.
   PubMed Web of Science ®Google Scholar
• Muraro A, Fokkens WJ, Pietikainen S, et al. European symposium on precision medicine in allergy and airways diseases: report of the european union parliament symposium (October 14, 2015). Allergy. 2016;71(5):583–587.
   PubMed Web of Science ®Google Scholar
• Kew KM, Undela K, Kotortsi I, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;(9):CD002997. DOI:10.1002/14651858.CD002997.pub2.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hamilos DL. Are antibiotics useful for chronic rhinosinusitis? J Allergy Clin Immunol Pract. 2016;4(4):629–638.
   PubMed Web of Science ®Google Scholar
• Alsharif S, Jonstam K, van Zele T, et al. Endoscopic sinus surgery for type‐2 CRS wNP: an endotype‐based retrospective study. Laryngoscope. 2019;129(6):1286–1292.
   PubMed Web of Science ®Google Scholar
• Dalziel K, Stein K, Round A, et al. Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol. 2006;20(5):506–519.
   PubMedGoogle Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019 May 15. DOI:10.1111/all.13875.
   Web of Science ®Google Scholar
• Manka LA, Wechsler ME. New biologics for allergic diseases. Expert Rev Clin Immunol. 2018;14(4):285–296.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New Engl J Med. 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.
   PubMed Web of Science ®Google Scholar
• Domingo C, Moreno A, Mirapeix R. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids. Intern Med J. 2011;41(7):525–536.
   PubMed Web of Science ®Google Scholar
• Busse W, Spector S, Rosen K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2103;132(2):485–486.
   Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019 July 24. DOI:10.1016/j.jaip.2019.07.016.
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16(2):233–242.
   PubMed Web of Science ®Google Scholar
• Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314(9):926–939.
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113(2):297–302.
   PubMed Web of Science ®Google Scholar
• Smith KA, Rudmik L. Medical therapy, refractory chronic rhinosinusitis, and productivity costs. Curr Opin Allergy Clin Immunol. 2017;17(1):5–11.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–825.
   PubMed Web of Science ®Google Scholar
• Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21(4):428–432.
   PubMedGoogle Scholar
• Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–324.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17(12):746–760.
   PubMed Web of Science ®Google Scholar
• Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117–129.
   PubMed Web of Science ®Google Scholar
• Singhal D, Psaltis AJ, Foreman A, et al. The impact of biofilms on outcomes after endoscopic sinus surgery. Am J Rhinol Allergy. 2010;24(3):169–174.
   PubMed Web of Science ®Google Scholar
• Bachert C, Wagenmann M, Hauser U, et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997;99(6 Pt 1):837–842.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437.
   PubMed Web of Science ®Google Scholar
• Ul-Haq Z, Naz S, Mesaik MA. Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev. 2016;32:3–15.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New Engl J Med. 2017;376(11):1090–1091.
   PubMedGoogle Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479.
   PubMed Web of Science ®Google Scholar
• Bachert C, Desrosiers M, Mullol J, et al. A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;143(2):AB433.
   Web of Science ®Google Scholar
• Han JK, Bachert C, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 Sinus-24 study. J Allergy Clin Immunol. 2019;143(2):AB422.
   Web of Science ®Google Scholar
• Falahati R, Bright J, Dorenbaum A, et al. A recombinant antibody to Siglec-8 shows selective ADCC activity against mast cells from systemic mastocytosis patients. Blood. 2015;126(23):4092.
   Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67(12):1572–1579.
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133(2):414–419.
   PubMed Web of Science ®Google Scholar
• Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol. 2011;23(7):415–420.
   PubMed Web of Science ®Google Scholar
• Krug N, Hohlfeld JM, Kirsten AM, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. New Engl J Med. 2015;372(21):1987–1995.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797–806.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar